NEW YORK, Sept. 18, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces the
RNS Number : 4123Z Renalytix AI PLC 18 September 2020 This announcement contains inside information Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI Reaches Milestone of KidneyIntelX Commercial Testing with Mount Sinai Health System NEW YORK , September 18, 2020 - Renalytix AI
RNS Number : 7366X Renalytix AI PLC 02 September 2020 Renalytix AI plc ("RenalytixAI", the "Company") Grant of Purchase Rights under the 2020 Employee Share Purchase Plan and Verici update NEW YORK , September 2, 2020 - Renalytix AI plc ( LSE: RENX) (NASDAQ: RNLX) announces that on 28
NEW YORK, Aug. 26, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, announces that it
RNS Number : 1457X Renalytix AI PLC 26 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI Files Submission Seeking U.S. FDA Clearance of KidneyIntelX NEW YORK , August 26, 2020 - Renalytix AI plc ( LSE: RENX) (NASDAQ: RNLX), an artificial intelligence -enabled in vitro
Parties to adopt multi-phase approach to develop precision medicine strategies to optimize treatment of cardiovascular, renal and metabolic disease NEW YORK, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), today announced a collaboration with AstraZeneca
RNS Number : 7551W Renalytix AI PLC 21 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") RenalytixAI to Collaborate with AstraZeneca to Improve Outcomes for Patients with Chronic Disease Parties to adopt multi-phase approach to develop precision medicine strategies to optimize
Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study to Assess 4,000 Surviving COVID-19 Patients NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Mount Sinai Health System and Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX), announce the initiation of a
RNS Number : 8477U Renalytix AI PLC 03 August 2020 Renalytix AI plc ("RenalytixAI", the "Company") KidneyIntelX in Multi-Center Study to Monitor and Predict Kidney Risk in COVID-19 Patients Surge in Chronic Kidney Disease and Kidney Failure Expected Post-COVID-19 Mount Sinai-Led Study
RNS Number : 8003U Renalytix AI PLC 31 July 2020 Renalytix AI plc (the "Company") Total Voting Rights For the purposes of DTR5.6.1R of the Transparency Directive, the Company notifies the market of the following: As of 31 July 2020 , the Company's issued and fully paid share capital
